Physician profile
Imran Nawaid Siddiqi
NPI 1942473285
$59,040.09
in general payments reported to CMS, 2019-2025
7 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Hematology (Pathology) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $8,313 · 2022: $39.58 · 2023: $51.64 · 2024: $7,775 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $33K · Travel and Lodging: $3,757 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $599 · Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $32,820.90 |
| Travel and Lodging | $3,756.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $599.44 |
| Food and Beverage | $277.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $37,128.28 | 2024-2025 | Sylvant |
| Agilent Technologies, INC. | $20,404.84 | 2019-2020 | |
| Seagen INC. | $1,125.00 | 2020 | |
| Medtronic, INC. | $291.45 | 2022-2025 | Midas Rex |
| Adaptive Biotechnologies Corporation | $51.64 | 2023 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $22.94 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $15.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Siddiqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.